Patents by Inventor Duane A. Mitchell

Duane A. Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220119762
    Abstract: Described herein are systems and methods relating to cellular micro-masonry. Systems and methods as described herein allow a user to create three-dimensional (3D) structures of cells disposed in a 3D culture medium. Systems and methods as described herein provide for the manipulation and construction of cellular structures on a single, cell-by-cell, basis.
    Type: Application
    Filed: December 30, 2021
    Publication date: April 21, 2022
    Inventors: Sarah V. ELLISON, Thomas Ettor ANGELINI, Scott Arthur BANKS, Duane MITCHELL, Cameron MORLEY, Catherine FLORES
  • Publication number: 20220031827
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Application
    Filed: July 11, 2021
    Publication date: February 3, 2022
    Applicant: Duke University
    Inventors: John H Sampson, Duane A Mitchell, Kristen A Batich, Michael D Gunn
  • Publication number: 20210317409
    Abstract: Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition.
    Type: Application
    Filed: March 22, 2017
    Publication date: October 14, 2021
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Maryam Rahman, Duane Mitchell, Rolando Lovaton, Hassan Azari
  • Publication number: 20210283184
    Abstract: The combination of adoptive cell therapy with CCR2 positive (CCR2+) hematopoietic stem cell transplantation increases T cell activation and survival.
    Type: Application
    Filed: December 21, 2017
    Publication date: September 16, 2021
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Duane Mitchell, Catherine Flores
  • Patent number: 11071777
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: July 27, 2021
    Assignee: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
  • Publication number: 20210170005
    Abstract: The present disclosure provides methods of increasing sensitivity of a tumor to treatment with an immune checkpoint inhibitor (ICI) in a subject and methods of treating a subject with an immune checkpoint inhibitor (ICI)-resistant tumor. The methods comprise administering to the subject a composition comprising a liposome comprising a cationic lipid and mRNA molecules, wherein the liposome is systemically administered to the subject. Also provided are methods of increasing the number of activated plasmacytoid dendritic cells (pDCs) in a subject in need thereof, comprising administering to the subject a composition comprising a liposome comprising a cationic lipid and mRNA molecules, wherein the liposome is systemically administered to the subject. Combination therapy with anti-PD-L1 mAb. Related methods of treatment and methods of preparing a dendritic cell vaccine are additionally provided.
    Type: Application
    Filed: August 15, 2019
    Publication date: June 10, 2021
    Inventors: Elias Sayour, Duane Mitchell
  • Publication number: 20210093670
    Abstract: The present disclosure provides methods for reducing Lewy Bodies in the central nervous system of a subject in need thereof by administering a T cell that is specific for an ?-synuclein mutant to the subject.
    Type: Application
    Filed: April 3, 2019
    Publication date: April 1, 2021
    Inventors: Vinata Vedam-Mai, Michael S. Okun, Catherine Flores, Duane Mitchell
  • Publication number: 20210077399
    Abstract: Provided herein is a liposome comprising ribonucleic acid (RNA) molecules, a lipid mixture comprising DOTAP and cholesterol, and iron oxide nanoparticles (IONPs). Also provided herein is a liposome comprising ribonucleic acid (RNA) molecules and a lipid mixture comprising DOTAP and cholesterol, wherein the DOTAP and cholesterol are present in the lipid mixture at a DOTAP:cholesterol ratio of about 3:1 by mass. Related cells comprising the liposome, populations of cells, and compositions are also provided. Methods of making a liposome and methods of using the liposome are further provided.
    Type: Application
    Filed: May 8, 2019
    Publication date: March 18, 2021
    Inventors: Adam J. Grippin, Duane Mitchell, Jon P. Dobson, Elias Sayour, Adam Monalve
  • Publication number: 20210008200
    Abstract: The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.
    Type: Application
    Filed: April 13, 2020
    Publication date: January 14, 2021
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Duane Mitchell, Catherine Flores
  • Publication number: 20210000944
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: July 24, 2020
    Publication date: January 7, 2021
    Applicant: Duke University
    Inventors: John H Sampson, Duane A Mitchell
  • Publication number: 20210000943
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: July 23, 2020
    Publication date: January 7, 2021
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell
  • Publication number: 20200345837
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: July 22, 2020
    Publication date: November 5, 2020
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell
  • Publication number: 20200332256
    Abstract: Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition.
    Type: Application
    Filed: March 22, 2017
    Publication date: October 22, 2020
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Maryam Rahman, Duane Mitchell, Rolando Lovaton, Hassan Azari
  • Publication number: 20200246452
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: March 18, 2020
    Publication date: August 6, 2020
    Applicant: Duke University
    Inventors: John H Sampson, Duane A Mitchell
  • Patent number: 10660954
    Abstract: The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: May 26, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Duane Mitchell, Catherine Flores
  • Patent number: 10632190
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: April 28, 2020
    Assignee: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell
  • Publication number: 20180236054
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Application
    Filed: April 19, 2018
    Publication date: August 23, 2018
    Applicant: Duke University
    Inventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
  • Publication number: 20180214544
    Abstract: The novel synergistic combination of immune checkpoint blockade and hematopoietic stem cell transplantation and/or hematopoietic stem cell mobilization yield synergistic effects in disease therapy.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 2, 2018
    Inventors: Duane Mitchell, Catherine Flores
  • Publication number: 20180215789
    Abstract: The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy. In fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Applicants: Duke University, Board of Regents, The University of Texas System
    Inventors: John H. Sampson, Darell D. Bigner, Duane A. Mitchell, Amy Heimberger
  • Publication number: 20180153982
    Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
    Type: Application
    Filed: August 14, 2017
    Publication date: June 7, 2018
    Inventors: John H. Sampson, Duane A. Mitchell